Lyrica (Pregabalin) for Restless Legs Syndrome

Pregabalin (sold as Lyrica) is now considered a first-line treatment for restless legs syndrome and carries a strong recommendation from the American Academy of Sleep Medicine, backed by moderate-certainty evidence.¹ That same guideline actually recommends against the routine use of pramipexole, the dopamine-based drug that dominated RLS prescribing for years. The shift reflects a growing understanding that RLS involves more than dopamine, and that pregabalin targets a piece of the puzzle dopamine agonists miss entirely.

Why RLS Happens and Where Pregabalin Fits In

For decades, RLS research centered on two problems in the brain: not enough iron and a misfiring dopamine system. The leading theory holds that low brain iron triggers changes in dopamine signaling, which produces the creeping, crawling urge to move your legs at rest.² That iron-dopamine link is supported by imaging studies, cerebrospinal fluid analyses, and autopsy data, and it explains why dopamine agonists can relieve symptoms.³

But dopamine is only part of the story. Brain iron deficiency also appears to push the brain into an overexcited state by ramping up glutamate, the nervous system’s main excitatory chemical.⁴ Imaging studies have found that people with RLS have higher glutamate levels in the thalamus compared to healthy controls, and that those elevated levels correlate with how much time the person spends awake during the night.⁵ This excess glutamate-driven arousal helps explain why RLS is not just about leg discomfort; it is fundamentally a sleep disorder, and why drugs that calm overexcited nerve signaling can work so well.

Pregabalin targets this excitatory side of the problem. It binds to a specific part of voltage-gated calcium channels on nerve cells, reducing calcium flow into the nerve terminal and dialing down the release of excitatory neurotransmitters like glutamate.⁶ An important detail: pregabalin preferentially acts on neurons that are already in a hyper-excited state, leaving normally functioning neurons mostly alone.⁷ That selectivity matters because it means the drug is not simply blanketing the brain with sedation; it is preferentially quieting the circuits that are misfiring.

What the Trials Show

Multiple randomized, placebo-controlled trials have tested pregabalin for RLS, and the results are consistently positive. In a dose-ranging study, researchers found that the treatment effect separated from placebo as early as the first week and continued growing through six weeks. The dose producing about 90 percent of the drug’s maximum symptom-reduction effect was roughly 124 mg per day.⁸ In another placebo-controlled trial, patients on pregabalin showed about a 63 percent improvement in their symptom scores, compared with roughly 38 percent for those on placebo.⁹

The most influential trial was published in the New England Journal of Medicine. Over 12 weeks, pregabalin beat placebo by an average of 4.5 points on the standard RLS rating scale, and about 71 percent of patients on pregabalin rated themselves “much improved” or “very much improved,” compared with about 47 percent on placebo.¹⁰ A 4.5-point gap on a 40-point scale might not sound dramatic, but in a condition where placebo responses are notoriously high, that separation was statistically strong and clinically meaningful.

Pregabalin Versus Dopamine Agonists

The same New England Journal of Medicine trial also compared pregabalin head-to-head with pramipexole, the dopamine agonist that had been a go-to RLS drug for years. On the primary symptom score, pregabalin and pramipexole produced similar improvements. But pregabalin separated itself in two ways that matter to patients: better sleep and a lower risk of augmentation.

Augmentation is the phenomenon where a dopamine agonist, after working well for months, gradually makes RLS worse. Symptoms start appearing earlier in the day, spread to the arms, or become more intense than they were before treatment started. It is one of the most frustrating aspects of RLS management, and it happens frequently enough with dopamine agonists that the AASM now recommends against using pramipexole as a standard treatment.¹¹ Pregabalin carries a much lower risk of augmentation, which is a major reason it has climbed to first-line status.¹²

If you are currently on pramipexole or ropinirole and doing fine, this does not necessarily mean you should switch immediately. But if you have been on a dopamine agonist for a long time and your symptoms have crept back or worsened, augmentation is a real possibility and pregabalin becomes a logical next step. That conversation is worth having with your prescriber.

The Sleep Advantage

One of the clearest edges pregabalin holds over dopamine agonists is its effect on sleep quality, which is measured not just by questionnaires but by objective sleep studies. In a polysomnography-based comparison, pregabalin reduced the time patients spent awake after falling asleep by about 27 minutes more than placebo, nearly identical to its advantage over pramipexole. It also cut the number of awakenings after sleep onset and increased subjective total sleep time by about 31 minutes over placebo.¹³

Perhaps the most interesting finding from that study was what happened to slow-wave sleep, the deep, restorative stage of sleep that the body depends on for physical recovery. Pregabalin increased slow-wave sleep duration by about 32 minutes compared to pramipexole. This is a meaningful difference, because people with RLS are often chronically short on deep sleep, and dopamine agonists do not help much on that front. Pregabalin’s ability to both reduce leg symptoms and improve sleep architecture is a big part of why it feels like a more complete treatment to many patients.

Typical Dosing

Pregabalin for RLS is taken as a single dose in the evening, usually one to three hours before bed. The starting dose is typically 75 mg, with gradual increases over several weeks depending on how well it is working and how well you tolerate it, up to a usual ceiling of about 300 mg.¹⁴ The dose-ranging data suggest that most of the drug’s benefit is captured well below 300 mg, so your prescriber will likely aim for the lowest effective dose.

One practical note: pregabalin is absorbed in a predictable, dose-proportional way, which means doubling the dose roughly doubles the blood level. This is a distinction from regular gabapentin, which is absorbed through a saturable transporter in the gut; at higher gabapentin doses, a smaller fraction actually gets into the bloodstream, making dose adjustments less predictable.¹⁵ For RLS patients, pregabalin’s linear absorption means you and your doctor can titrate the dose more confidently.

Side Effects

The most common side effects across trials are dizziness and drowsiness.¹⁶ Because pregabalin is taken at bedtime for RLS, the drowsiness is less of an issue than it would be for someone taking it during the day for nerve pain or anxiety. Dizziness, however, can be a problem, especially in the first week or two and especially in older adults. Starting at the lower 75 mg dose and going up slowly helps.

Other side effects that come up in the literature include weight gain, peripheral edema (puffy ankles and feet), dry mouth, and blurred vision. These tend to be dose-dependent, meaning they become more likely and more pronounced at higher doses. Weight gain, in particular, can be a deal-breaker for some people over the long term. If you notice your shoes getting tighter or the scale creeping up, mention it early rather than waiting. A dose adjustment or switch to a different alpha-2-delta ligand may help.

One side effect worth flagging separately is euphoria. In clinical trials for various conditions, some patients report a pleasant, “buzzed” feeling, especially early in treatment. This is part of why pregabalin carries abuse-potential concerns, discussed below.

Abuse Potential and Scheduling

Pregabalin is classified as a Schedule V controlled substance in the United States, the lowest level of scheduling. This classification reflects a recognized, if relatively low, potential for misuse. A systematic review found that euphoria is a frequently reported side effect, and that most documented cases of pregabalin abuse involved people who already had a history of substance use disorders, particularly opioid dependence.¹⁷

Animal research has added nuance. In a study using a standard reward-testing model, mice showed a clear preference for environments associated with pregabalin at moderate and high doses, suggesting the drug can produce rewarding effects in the brain.¹⁸ This does not mean everyone who takes Lyrica for RLS is at risk, but prescribers are advised to be more cautious with patients who have a history of addiction. For most RLS patients without that history, the risk at the relatively low doses used for RLS appears to be small. Still, you should be aware of it and honest with your doctor about your history.

Outside the United States, some countries have taken a stricter approach. The United Kingdom reclassified pregabalin as a Class C controlled substance in 2019, partly in response to rising misuse and pregabalin-related deaths in populations with polysubstance use. The practical implication for RLS patients is that refill policies can be tighter than for an unscheduled medication, and you should plan ahead to avoid gaps in treatment.

Pregnancy and Pediatric Use

RLS becomes more common during pregnancy, especially in the third trimester, and the question of what is safe to take comes up frequently. Pregabalin is not recommended during pregnancy or breastfeeding because safety data in those populations are simply lacking.¹⁹ The same goes for gabapentin enacarbil. If you are pregnant or planning to become pregnant and have RLS, the first-line approach is usually non-drug strategies: iron supplementation if your ferritin is low, leg stretches, avoiding caffeine in the evening, and maintaining good sleep hygiene. Prescription options in pregnancy are limited and involve a careful risk-benefit discussion.

Pregabalin is also not well studied in children and adolescents with RLS. While pediatric RLS exists and can be disruptive, the evidence base for drug treatment in that age group is thin for essentially every medication, not just pregabalin. Iron status is usually the first thing checked, and behavioral strategies come before medication in most pediatric guidelines.

How Pregabalin Compares to Gabapentin and Gabapentin Enacarbil

Pregabalin belongs to a class of drugs called alpha-2-delta ligands, and it is not the only one used for RLS. Regular gabapentin (Neurontin) and gabapentin enacarbil (Horizant) work by the same basic mechanism. Gabapentin enacarbil is actually the only alpha-2-delta ligand with an FDA-approved indication specifically for RLS, whereas pregabalin is prescribed off-label for it. A network meta-analysis pooling data from 35 trials and over 7,300 participants found that gabapentin enacarbil, pregabalin, and rotigotine (a dopamine agonist patch) all reduced RLS symptom scores by about five points more than placebo, with no significant differences between the three active drugs.²⁰

If they are equally effective, why might a prescriber choose one over the other? A few practical factors come into play:

Absorption: Regular gabapentin has unpredictable absorption at higher doses. Pregabalin and gabapentin enacarbil both have more predictable dose-response curves, which can make titration smoother.
Cost: Pregabalin is now available as a generic, which has made it more affordable. Gabapentin enacarbil remains brand-name only in most markets and can be substantially more expensive.
Scheduling: Pregabalin is a Schedule V controlled substance; gabapentin and gabapentin enacarbil are not federally scheduled in the U.S. (though some states have added gabapentin to their prescription monitoring programs). For patients where scheduling creates logistical barriers, gabapentin may be simpler.
Insurance coverage: Because gabapentin enacarbil is the only one with an actual RLS indication, some insurers cover it more readily for that diagnosis. Others prefer the cheaper generic pregabalin or generic gabapentin. This is often decided case by case.

When Pregabalin Is Not Enough

For most people with moderate-to-severe RLS, pregabalin at appropriate doses provides meaningful relief. But RLS exists on a spectrum, and a subset of patients has severe or refractory symptoms that do not respond adequately to a single medication. In those cases, clinicians sometimes add a low-dose dopamine agonist to an alpha-2-delta ligand, or bring in other strategies entirely.

A study examining pregabalin as an add-on therapy in patients who were already on other RLS medications found that adding pregabalin significantly lowered average symptom scores and improved insomnia ratings.²¹ This supports the idea that pregabalin can be layered into a treatment plan when monotherapy is not doing enough. Iron infusion is another option for refractory cases, especially when serum ferritin is below 75 micrograms per liter, since correcting iron deficiency addresses one of the upstream causes rather than just managing symptoms.

The Glutamate Connection and Future Directions

The fact that pregabalin works in RLS has reinforced a shift in how researchers think about the condition. For years, the dopamine hypothesis dominated, and dopamine agonists were the default. The clinical success of alpha-2-delta ligands, combined with imaging studies showing elevated thalamic glutamate in RLS patients, has brought glutamate signaling into sharper focus.²² Research now frames RLS as involving a hyperarousal state driven partly by excess glutamate acting on circuits connecting the cortex, striatum, and thalamus.²³

This reframing matters beyond academic interest. If RLS is partly a disorder of neural excitability rather than purely a dopamine problem, it opens the door to other treatments that modulate excitatory signaling. Researchers are exploring whether other drugs that act on glutamate pathways might help, and whether combining approaches that address both dopamine and glutamate could yield better results for people who respond poorly to either alone. Animal studies on pregabalin’s effects on reward and glutamate pathways have also raised questions about how precisely the drug interacts with these systems, suggesting the pharmacology is more complex than a simple calcium-channel story.²⁴ The field is still working out the details, but the practical upshot is that treatments are getting better because the understanding of RLS itself is getting more nuanced.